How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Sell
12
IRON Quote, Financials, Valuation and Earnings
Last price:
$49.67
Seasonality move
:
15.39%
Day range:
$48.05 - $51.78
52-week range:
$25.60 - $68.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.87x
Volume:
754.8K
Avg. volume:
368.2K
1-year change:
-20.27%
Market cap:
$1.7B
Revenue:
--
EPS (TTM):
-$3.99
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IRON
Disc Medicine
|
-- | -$1.11 | -- | -2.04% | $97.82 |
|
INVA
Innoviva
|
$80.3M | $0.41 | 3.55% | -46.05% | $19.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -100% | -67.93% | $7.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IRON
Disc Medicine
|
$49.64 | $97.82 | $1.7B | -- | $0.00 | 0% | -- |
|
INVA
Innoviva
|
$18.13 | $19.00 | $1.1B | 95.42x | $0.00 | 0% | 4.01x |
|
NBY
NovaBay Pharmaceuticals
|
$0.59 | $0.85 | $2.9M | -- | $0.00 | 0% | 0.06x |
|
OGEN
Oragenics
|
$0.21 | $1.00 | $4.5M | -- | $0.00 | 0% | 1.31x |
|
PTN
Palatin Technologies
|
$0.58 | $7.00 | $15.2M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.10 | $6.00 | $3.1M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IRON
Disc Medicine
|
-- | 5.300 | -- | -- |
|
INVA
Innoviva
|
39.35% | 0.503 | 41.24% | 2.11x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.451 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 3.461 | -- | -- |
|
PTN
Palatin Technologies
|
-- | 0.220 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.635 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IRON
Disc Medicine
|
-- | -$34.6M | -- | -- | -- | -$28M |
|
INVA
Innoviva
|
$84.6M | $43.1M | 2.07% | 3.44% | 32.07% | $55.2M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
-- | -$5.1M | -- | -- | -2356.3% | -$4.8M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Disc Medicine vs. Competitors
-
Which has Higher Returns IRON or INVA?
Innoviva has a net margin of -- compared to Disc Medicine's net margin of 22.15%. Disc Medicine's return on equity of -- beat Innoviva's return on equity of 3.44%.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$0.98 -- INVAInnoviva92.2% $0.26 $1.1B -
What do Analysts Say About IRON or INVA?
Disc Medicine has a consensus price target of $97.82, signalling upside risk potential of 97.06%. On the other hand Innoviva has an analysts' consensus of $19.00 which suggests that it could grow by 4.8%. Given that Disc Medicine has higher upside potential than Innoviva, analysts believe Disc Medicine is more attractive than Innoviva.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 INVAInnoviva0 1 0 -
Is IRON or INVA More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innoviva has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.553%.
-
Which is a Better Dividend Stock IRON or INVA?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or INVA?
Disc Medicine quarterly revenues are --, which are smaller than Innoviva quarterly revenues of $91.8M. Disc Medicine's net income of -$29.5M is lower than Innoviva's net income of $20.3M. Notably, Disc Medicine's price-to-earnings ratio is -- while Innoviva's PE ratio is 95.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 4.01x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$29.5M INVAInnoviva4.01x 95.42x $91.8M $20.3M
-
Which has Higher Returns IRON or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Disc Medicine's net margin of -49.65%. Disc Medicine's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$0.98 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About IRON or NBY?
Disc Medicine has a consensus price target of $97.82, signalling upside risk potential of 97.06%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 45.3%. Given that Disc Medicine has higher upside potential than NovaBay Pharmaceuticals, analysts believe Disc Medicine is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is IRON or NBY More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.
-
Which is a Better Dividend Stock IRON or NBY?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or NBY?
Disc Medicine quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Disc Medicine's net income of -$29.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Disc Medicine's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$29.5M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns IRON or OGEN?
Oragenics has a net margin of -- compared to Disc Medicine's net margin of --. Disc Medicine's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$0.98 -- OGENOragenics-- -$0.27 -- -
What do Analysts Say About IRON or OGEN?
Disc Medicine has a consensus price target of $97.82, signalling upside risk potential of 97.06%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 376.19%. Given that Oragenics has higher upside potential than Disc Medicine, analysts believe Oragenics is more attractive than Disc Medicine.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 OGENOragenics0 1 0 -
Is IRON or OGEN More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.
-
Which is a Better Dividend Stock IRON or OGEN?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or OGEN?
Disc Medicine quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Disc Medicine's net income of -$29.5M is lower than Oragenics's net income of -$3.3M. Notably, Disc Medicine's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 1.31x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$29.5M OGENOragenics1.31x -- -- -$3.3M
-
Which has Higher Returns IRON or PTN?
Palatin Technologies has a net margin of -- compared to Disc Medicine's net margin of -2357.27%. Disc Medicine's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$0.98 -- PTNPalatin Technologies-- -$0.12 -$111.5K -
What do Analysts Say About IRON or PTN?
Disc Medicine has a consensus price target of $97.82, signalling upside risk potential of 97.06%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1100.89%. Given that Palatin Technologies has higher upside potential than Disc Medicine, analysts believe Palatin Technologies is more attractive than Disc Medicine.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 PTNPalatin Technologies0 0 0 -
Is IRON or PTN More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.
-
Which is a Better Dividend Stock IRON or PTN?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or PTN?
Disc Medicine quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Disc Medicine's net income of -$29.5M is lower than Palatin Technologies's net income of -$2.4M. Notably, Disc Medicine's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$29.5M PTNPalatin Technologies-- -- $350K -$2.4M
-
Which has Higher Returns IRON or TOVX?
Theriva Biologics has a net margin of -- compared to Disc Medicine's net margin of --. Disc Medicine's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$0.98 -- TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About IRON or TOVX?
Disc Medicine has a consensus price target of $97.82, signalling upside risk potential of 97.06%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 445.46%. Given that Theriva Biologics has higher upside potential than Disc Medicine, analysts believe Theriva Biologics is more attractive than Disc Medicine.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 TOVXTheriva Biologics0 0 0 -
Is IRON or TOVX More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.
-
Which is a Better Dividend Stock IRON or TOVX?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or TOVX?
Disc Medicine quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Disc Medicine's net income of -$29.5M is lower than Theriva Biologics's net income of -$4.4M. Notably, Disc Medicine's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$29.5M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is up 109.21% over the past day.
Sell
47
RGC alert for Apr 1
Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 14.4% over the past day.
